Niti Dube, Author at PreludeDx

About Niti Dube

Niti Dube, MD is a Board-Certified Radiation Oncologist who earned her undergraduate degree in biology at the Massachusetts Institute of Technology in Cambridge, MA followed by her Doctor of Medicine degree from the Albert Einstein College of Medicine in Bronx, NY. Her residency was completed at New York Presbyterian Hospital-Weill Cornell Medical Center where she served as Chief Resident in radiation oncology and received the Distinguished Housestaff Award. Dr. Dube’s has vast experience in treating many malignancies, including breast, prostate, brain, lung, gastrointestinal, and gynecologic tumors, with a focus experience as a breast cancer specialist. Dr. Dube’s experience for breast cancer radiotherapy includes Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT), partial breast irradiation (PBI), as well as Breast HDR (high dose rate) Brachytherapy Radiation. She also has extensive experience in stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Dr. Dube lectures about breast cancer treatment and participates in cancer awareness events in the community. She is an active member of the American Society of Therapeutic Radiology and Oncology and American Radium Society. She has been recognized as Castle Connolly Top Doctor, NY Magazine NY Top Doctor and Exceptional Women in Medicine as well a Westchester Magazine Top Doctor.

DCIS Case Studies: Surgeon Roundtable

In this webinar, Eric Brown, MD, FACS; Erica Giblin, MD; James V. Pellicane, MD; Troy Bremer, PhD; and Leona Hamrick, DHSc, PA-C, MSL-BC, discuss how DCISionRT and its newly integrated Residual Risk Subtype (RRt) played a significant role in treatment decision making in DCIS patients identified in the RRt category. These key opinion leaders discuss actual patient cases with RRt, the differentiating factors among cases, patient preference and final treatment decisions.

Niti Dube2024-01-16T16:33:27-06:00January 16th, 2024|

“My DCIS patients are really excited about the DCISionRT test. It makes them feel empowered and an active member of the decision-making process.”

“I send every qualified patient I see with ductal carcinoma in situ (#DCIS) for the #DCISionRT test, even the ones with a tiny low-grade lesion, because sometimes the test reveals an elevated risk recurrence score, which is surprising. And I never want to miss offering radiation modality options to patients who will benefit. I have seen the greatest decision impact on those women who were not inclined to undergo radiation but when their DCISion score is high, they choose to proceed with radiation.”

Niti Dube2023-11-14T12:34:44-06:00November 14th, 2023|